S2-E47 – Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer

Ian Rowe, Michelle Long and Manal Abdelmalek reveal what they consider the most important NAFLD/NASH stories of summer.

Which NAFLD/NASH stories of Summer did they choose? The newly-appointed Professor Rowe discusses the importance of the FDA approval of the ELF test as a prognostic for cirrhosis. True to her epidemiological background, Professor Long reviews the prospective prevalence study that Stephen Harrison, Naim Alkhouri and others conducted in San Antonio. Finally, Professor Abdelmalek uses a comment she received at a presentation this summer as a jumping-off point to discuss potential value currently available generic drugs — metformin, statins, carvedilol — in treating portal pressure among cirrhosis patients. Some highlights:

4:39 – Ian Rowe’s understated announcement
6:31 – Ian’s event: FDA approves ELF
9:49 – ELF (and other NITs) will improve risk stratification by replacing ordinal Fibrosis scores with continuous test results
11:37 – Louise Campbell raises the issue of testing for the increasing NAFLD/NASH prevalence in Third World countries with fewer resources than the West has
13:02 – Ian notes that widespread population screening must start with a simple, inexpensive test, even in wealthier countries
14:54 – Roger Green raises the value of visual (picture) test results and asks how blood-based tests can overcome the fact that they do not produce pictures. Discussion and friendly debate about relative value of risk scores and visual outputs ensues.
18:39 – Ian discusses his work on patients’ understanding of cirrhosis, which demonstrates the value of nursing in cirrhosis care clinics. Louise amplifies his point.
22:34 – Wrap-up question for Ian’s interview
24:20 – Conversation with Michelle Long begins
26:49 – MIchelle’s event: Stephen Harrison and Naim Alkhouri’s paper on “Prospective Evaluation of the Prevalence of Fatty Liver Disease and NASH in an Unselected Middle-age Cohort”
28:28 – MIchelle mentions NAFLD/NASH prevalence rates among study participants
32:35 – Louise revealed what she learned in a high-level qualitative scan of patient records
33:36 – Louise discusses recent paper on the long-term of simple steatosis
35:27 – Louise wonders about the level of NAFLD/NASH education and awareness among endocrinologists.
40:10 – Louise raises the idea of scanning patients who have come to physician for other procedures, just as Stephen did in the prevalence study
44:56 – Conversation with Manal Abdelmalek begins
47:40 – Manal’s event: NIH funding the new liver cirrhosis network
49:22 – Manal focuses on the urgency of doctors and patient today, the need to propose helpful therapies. At 50:30, she discusses a recent single-dose 1000mg metformin study checking its effect on portal pressure in patients with cirrhosis.
53:35 – Manal notes that statins, beta blockers have some reported positive effects in cirrhosis
56:27 – Roger raises the idea of maintaining fibrosis level as a clinically meaningful endpoint for approval
59:28 – Louise describes a way that even general practice physicians can track cirrhosis using their FibroScan machines or other equipment
1:03:19 – Manal raises the idea that this is drug help we can provide for some patients now, before approval
1:07:19 – Closing question for the third conversation
1:10:32 – Business section

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"